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questionnaires. During a face-to-face meeting on June 
21, 2015, attended by 38 experts, all data from the online 
rounds were reviewed and recommendations for definitions 
were formulated.
Results Consensus was attained on 23 of 27 topics; Tar-
geted FT was defined as a lesion-based treatment strat-
egy, treating all identified significant cancer foci; FT was 
generically defined as an anatomy-based (zonal) treatment 
strategy. Treatment failure due to the ablative energy inad-
equately destroying treated tissue is defined as ablation 
Abstract 
Purpose To reach standardized terminology in focal ther-
apy (FT) for prostate cancer (PCa).
Methods A four-stage modified Delphi consensus pro-
ject was undertaken among a panel of international experts 
in the field of FT for PCa. Data on terminology in FT 
was collected from the panel by three rounds of online 
Electronic supplementary material The online version of this 
article (doi:10.1007/s00345-016-1782-x) contains supplementary 
material, which is available to authorized users.
 * A. W. Postema 
 a.w.postema@amc.uva.nl
1 Departments of Urology, AMC University Hospital, 
Amsterdam, The Netherlands
2 Departments of Radiation Oncology, AMC University 
Hospital, Amsterdam, The Netherlands
3 USC Institute of Urology, Keck School of Medicine, 
University of Southern California, Los Angeles, CA, USA
4 Department of Urology, Kyoto Prefectural University 
of Medicine, Kyoto, Japan
5 Department of Urology, Angers University Hospital, Angers, 
France
6 Department of Urology, Institut Montsouris, Université Paris 
Descartes, Paris, France
7 Department of Urology, Magdeburg University Medical 
Center, Magdeburg, Germany
8 Department of Urology, Fuerth Hospital, Fuerth, Germany
9 Department of Radiation Oncology, Gustave Roussy 
Institute, Villejuif, France
10 Department of Urology, Ospedale Civile Ramazzini, Carpi, 
Italy
11 Department of Surgery, Memorial Sloan-Kettering Cancer 
Center, New York, NY, USA
12 Department of Urology and Transplantation, Edouard Herriot 
Hospital, Lyon, France
13 Department of Urology, Instituto Valenciano de Oncología, 
Valencia, Spain
14 Department of Urology, University of Chicago, Chicago, IL, 
USA
15 Department of Urology, University of Leipzig, Leipzig, 
Germany
16 Joint Department of Medical Imaging, University Health 
Network, University of Toronto, Toronto, Canada
17 Departments of Radiology, Duke University Medical Center, 
Durham, NC, USA
18 Departments of Surgery, Duke University Medical Center, 
Durham, NC, USA
19 Urologische Praxis Dr. Henkel & Dr. Kahmann, Berlin, 
Germany
1374 World J Urol (2016) 34:1373–1382
1 3
failure. In targeting failure the energy is not adequately 
applied to the tumor spatially and selection failure occurs 
when a patient was wrongfully selected for FT. No defi-
nition of biochemical recurrence can be recommended 
based on the current data. Important definitions for out-
come measures are potency (minimum IIEF-5 score of 21), 
incontinence (new need for pads or leakage) and deteriora-
tion in urinary function (increase in IPSS >5 points). No 
agreement on the best quality of life tool was established, 
but UCLA-EPIC and EORTC-QLQ-30 were most com-
monly supported by the experts. A complete overview of 
statements is presented in the text.
Conclusion Focal therapy is an emerging field of PCa 
therapeutics. Standardization of definitions helps to create 
comparable research results and facilitate clear communi-
cation in clinical practice.
Keywords Focal therapy · Prostate cancer · Consensus · 
Definitions · Standardization · Outcome
Introduction
Prostate cancer (PCa) is traditionally treated with whole-
gland treatments such as radical prostatectomy, whole-
gland external beam radiotherapy and whole-gland brachy-
therapy [1]. Active surveillance allows selected patients 
with low-risk PCa to postpone or avoid radical treatment 
and the associated risk of toxicity [1]. Focal therapy (FT) 
is a fairly recent and rapidly developing field of PCa treat-
ment where only a portion of the prostate gland is treated. 
Focal therapy intends to strike a balance between treating 
what must be treated while minimizing toxicity [2]. Differ-
ent ablative energies employed for FT and under investiga-
tion include: cryosurgery, high-intensity focused ultrasound 
(HIFU), irreversible electroporation (IRE), laser ablation 
therapy, photodynamic therapy, and brachytherapy [3]. In 
the accumulating literature on FT, different terminology 
is used for different variants of tissue-sparing treatments, 
targeted lesions, and oncologic, functional and procedural 
outcomes. Standardization in definitions will aid in creating 
comparable research results in the literature and with clear 
communication in clinical settings. To achieve widely rec-
ognized standardized terminology in FT, we conducted an 
international multidisciplinary consensus project.
Methods
The Delphi method is a widely accepted method to achieve 
consensus among experts and is employed in economics, 
politics, military decision making and medicine [4]. The 
basis of the Delphi method is that a panel of experts is 
repeatedly presented a series of questions. Each successive 
round the question and answer possibilities are modified 
based on the responses to the previous round. The anony-
mous aggregated results and comments of the previous 
round are presented to the panel, allowing the participants 
to reassess their opinion. The intended outcome is a conver-
gence of opinions with a minimized effect of peer-pressure 
and dominant individuals influencing group choices.
A systematic literature search of the English literature 
was conducted on “prostate cancer”, “focal therapy” and 
the various FT modalities. The initial search yielded 190 
results with subsequent automatic filtering, screening of 
titles, abstracts and full-texts resulting in the selection of 
25 papers for data extraction. The search term and results 
are provided in Fig. 1. A group of 113 experts was invited 
to participate on the basis of the literature search and peer 
recommendation.
From the papers identified by the systematic search, 
various definitions of oncologic, functional and proce-
dural outcomes were extracted and these data formed 
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the basis of the questionnaires. The questionnaires con-
structed were presented to the participants in three suc-
cessive rounds between May 15 and June 16, 2015 (using 
www.surveymonkey.com). The level of agreement neces-
sary to achieve consensus was set at 80 %. During the 8th 
International Symposium on Focal Therapy and Imaging 
in Prostate & Kidney Cancer (www.focaltherapy.org), a 
face-to-face meeting was held among 38 of the experts. 
All results from the online questionnaires were presented 
and discussed. Topics on which the online panel had 
achieved consensus were not overturned. Topics on which 
consensus had not been achieved were discussed in detail. 
Recommendations for definitions were formulated on all 
topics. An overview of the results of the online rounds 




Twenty-five reports of clinical trials and trial proto-
cols describing oncological, functional and procedural 
outcomes after a focal treatment, published after 2005, 
were identified by the systematic search. The modalities 
described were cryoablation [5–12], HIFU [6, 13–17], IRE 
[6, 13–21], laser ablation therapy [22–24], VTP [6, 25–28] 
and brachytherapy [6, 29].
Treatment efficacy
Commonly reported measures of treatment efficacy are 
prostate-specific antigen (PSA) dynamics after treat-
ment [5–17, 20–22, 25, 26, 28, 29], the presence of sus-
picious areas on follow-up MRI [13, 14, 16, 18, 20–22, 
25] and follow-up biopsy results. The planned follow-up 
biopsy scheme varies: in some protocols both the treated 
zone and the untreated zone are biopsied in every patient 
[5, 7–11, 15, 17, 19, 25–27, 29]. In other protocols, only 
the treated zone is biopsied [22, 28], although some groups 
add biopsies from the untreated zone if new lesions are 
found on imaging [13, 14, 21]. Lee et al. [24] biopsied the 
ablated zone only at 3 months and performed a 12-core 
systematic biopsy and additional ablated zone biopsies at 
1 year. Dickinson et al. [16] described treated zone biop-
sies at 1 year and template mapping biopsies at 3 years. 
Few authors define treatment success and failure, and the 
definitions vary: Ellis et al. [8] described an argument for 
only considering cancer found at follow-up in the treated 
zone or development of metastatic disease as treatment 
failure. Lindner et al. [27] referred to their four cases with 
residual tumor in the treated zone as treatment failures. 
Azzouzi et al. [25] defined a negative follow-up biopsy of 
the targeted zones as treatment success. In their protocol, 
Dickinson et al. [16] determined cancer control as the pri-
mary outcome using two definitions: (1) the combination 
of being free of any cancer in the treated zone and free of 
significant cancer in untreated zones at 3-year template 
Fig. 1  Systematic search
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biopsy or (2) free of significant disease in both treated and 
untreated zone at 3-year template biopsies. Onik et al. [11] 
proposed to define the combination of stable PSA and neg-
ative follow-up biopsy as a successful result. Durand et al. 
[7] defined treatment failure as positive follow-up biopsy 
in the treated lobe or biochemical failure according to the 
Phoenix criteria of PSA nadir +2 ng/mL at 18 months.
Trifecta
Trifecta as a measure for urinary continence, potency and 
cancer control is defined by three papers, although two dif-
ferent definitions were used: pad-free, leak-free continence, 
erections sufficient for penetration and no high volume 
disease or Gleason ≥7 disease on follow-up biopsies were 
used in two papers [13, 21]. Ahmeds’ et al. [14] definition 
differed by substituting a radiologic outcome for the biopsy 
outcome of using no evidence of clinical disease on MRI at 
12 months as a surrogate for cancer control.
Significant cancer
All papers that defined clinically significant disease at 
biopsy agreed that Gleason ≥7 is significant at any cancer 
core length. The maximum length of Gleason 6 that is con-
sidered insignificant is 2 mm [14] or 3 mm [13, 16, 20, 21].
Radiographic failure
Several authors used imaging to determine whether resid-
ual tumor in the treated zone or new tumor outside the 
treated zone was present. Six papers reported the use of 
MRI [13, 14, 21, 22, 24, 29] and one additional paper [20] 
also defined criteria for suspicion of residual cancer: an 
early enhancing focus on the dynamic contrast sequence 
and residual restricted diffusion in the treatment area. 
Doppler ultrasound was used to target suspicious lesions 
post-treatment in one study [5]. One protocol described 
using both MRI and transrectal ultrasonography at 1, 3 and 
5 years post-treatment without stating the purpose of these 
investigations [18].
Biochemical status
Baseline and post-treatment PSA dynamics are reported by 
most papers [5–22, 24–29]. The more specific “biochemi-
cal recurrence” is reported by few papers and different defi-
nitions were used: The original ASTRO definition of three 
consecutive rises above the nadir was used by five authors 
[5, 8, 10, 11, 17]. Durand et al. [7] used the Phoenix defini-
tion of PSA nadir +2 ng/mL. Lambert et al. [9] described 
two conditions, meeting either one was considered bio-
chemical recurrence: PSA nadir +2 ng/mL or a PSA nadir 
of less than 50 % of the pre-treatment level. Nguyen et al. 
[29] advocated an alternative definition of biochemical 
recurrence where two conditions should both be met: PSA 
nadir +2 ng/mL and a PSA velocity over 0.75 ng/mL.
Sexual function
Sexual function is most commonly reported using the Inter-
national Index of Erectile Function 5 item version (IIEF-
5), alternatively known as the Sexual Health Inventory for 
Men [6, 7, 15, 18, 19, 22, 24, 25, 27]. Durand et al. [7] 
defined an IIEF-5 score between 21 and 25 regardless of 
oral medication use as potent. The 15 item version (IIEF-
15) was used by four authors [6–8, 10]. Two papers used 
the Brief Male Sexual Function Inventory BMSFI [5, 28, 
30]. Six papers did not report the use of a validated ques-
tionnaire but did state the proportion of patients who were 
potent following FT [8–12, 20]. Four papers did not report 
sexual function [17, 23, 26, 29]. Different definitions for 
potency were in use besides the standardized question-
naires: the combination of achieving erections sufficient for 
vaginal penetration and being satisfied with sexual func-
tioning regardless of the use of oral medication [10, 11], 
erections sufficient for vaginal penetration allowing phos-
phodiesterase-5 inhibitors [8, 14], erections sufficient for 
vaginal penetration without stating whether medication is 
allowed [9, 13, 20, 21], and the ability to maintain an erec-
tion when stimulated with or without oral medication [5]. 
However, many papers that reported potency as an outcome 
did not state how it is defined [6, 12, 15, 16, 18, 19, 22, 
24, 25, 27, 28]. Durand et al. [7] reported the number of 
patients who are sexually active before and after treatment 
without providing a definition.
Urinary function
The most commonly used measure of urinary function was the 
IPSS [6, 7, 13–19, 21, 22, 24, 25, 27, 28]. The UCLA-EPIC 
urinary domain was used by six papers [13, 14, 16, 17, 19, 21, 
24]. Continence was reported by several authors without pro-
viding an exact definition [6, 9, 12, 23, 24]. Commonly used 
definitions for incontinence were: the use of pads [7, 10, 11, 
14, 20], urinary leakage [5, 8] or combined: urinary leakage or 
pads [13, 14, 21]. One paper described the use of the Interna-
tional Continence Society questionnaire [15].
Bowel function
The UCLA-EPIC bowel domain was mentioned by two 
papers [16, 21]. Other authors simply stated the absence of 
fistula, rectal discomfort, rectal bleeding, and change in fre-
quency [14, 20, 22]. No definition for bowel toxicity in the 
context of FT was provided.
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Quality of life
Quality of life (QoL) was generally reported based on 
standardized questionnaires. The UCLA-EPIC [13, 14, 
16, 17, 19, 21, 24, 31] and FACIT (FACT-P and FACT-G) 
[13, 14, 16, 18, 21, 32, 33] were most prevalent in the 25 
papers identified by the literature search. Other question-
naires used were MAX-PC [16, 21, 34], EORTC-QLQ-30 
[15, 35], PORPUS [27, 36] and EQ-5D [16, 21, 37]. No 
specific definitions or cut-off values for the questionnaires 
were provided.
Complications
For the timing and severity of complications, several defi-
nitions and systems were used. Perioperative or periproce-
dural complications were reported but not exactly defined 
by three papers [19, 22, 27]. Many authors used either the 
Clavien–Dindo score [6, 7] or the Common Terminology 
Criteria for scoring Adverse Events (CTCEA) scoring sys-
tem to grade adverse events [19, 20, 22, 25]. A CTCEA 
grade 3 and above and Clavien grade 3a and above were 
considered “severe”. Moore et al. [28] described minor 
complications without providing a definition [28].
Procedural outcomes
Procedure time was reported by five papers and two did 
not provide a precise description [7, 13, 23]. Oto et al. [22] 
reported the total time the patient spends in the MR unit. 
Azzouzi et al. [25] reported the procedure time including 
anesthesia, targeting and ablation. Most papers stated how 
many days the urethral catheter was left in situ following 
FT [6–8, 12, 17–19, 22, 23, 27, 28]. Many authors provided 
the time the patient remained in the hospital after FT [6–8, 
13, 14, 18–20, 22, 23, 27]. Dickinson et al. [16] implied 
that treatment in day-care per definition does not involve an 
overnight stay.
Consensus project: response rates and participants
One hundred thirteen experts were invited to participate. 
The response rate was 59 % (67/113) for the first round, 
53 % (60/113) for the second and 65 % (73/113) for the 
third round. Complete personal details were collected dur-
ing the last online round and showed the following partici-
pant backgrounds: 75 % were urologists, 11 % radiologists, 
4 % radiotherapists, 4 % researchers, 3 % pathologists and 
3 % medical oncologists. The average number of patients 
treated with FT annually reported by the panelists was 
10–50 (47 %), 7 % of participants treated over 100 patients 
a year with FT. Cryosurgery, HIFU and brachytherapy were 
the most commonly used treatment modalities among the 
panel with 48, 51 and 29 % of the panelists reporting expe-
rience with these techniques. All consensus statements are 
summarized in Table 1. All registered participants to the 
online rounds and results of the online rounds discussed at 
the meeting are made available through Appendices 1 and 
2, respectively.
General definitions
The panel recommends defining “targeted focal therapy” as 
a lesion-based focal treatment of the target lesion(s) plus 
a safety margin. Ablating a quadrant, a lobe (hemiabla-
tion) or both lobes sub-totally would be defined as “focal 
therapy”. Other variants of these anatomy-based focal 
therapy templates are subtotal ablation (any ablation where 
less than the whole gland is treated) and extended hemi-
ablation (an ablation where one lobe is completely treated 
plus a margin of the other lobe, regardless of shape). The 
aim of targeted focal therapy should be the eradication of 
all identified significant tumors. There was agreement the 
index lesion is the single dominant lesion in terms of grade 
and size; grade being more important. Although there was 
agreement that there can be only 1 index lesion, the term 
“index lesion” itself may be of limited clinical use in the 
context of FT. When there are multiple significant lesions, 
it is more important to have an overview of all lesions that 
require treatment rather than a single defined index lesion.
There was no consensus on the definition of salvage 
focal therapy during the online rounds. After discussion at 
the meeting, the panel supported the following statement: 
Salvage focal therapy refers to a situation where focal treat-
ment is applied to the prostate after previous whole-gland 
therapy, or in the same region of the prostate as a previous 
FT. The prostate gland has to be in place.
Success and failure in focal therapy
In defining success and failure of FT, two levels were 
observed by the panel during the meeting: Failure of the 
focal treatment as a whole and several reasons for a focal 
treatment to fail (“ablation failure”, “targeting failure” and 
“selection failure”). Ablation failure is a failure of the tech-
nique to destroy the tissue within the intended treated zone, 
evidenced by tumor detected within the treated zone. Abla-
tion failure must be confirmed histologically. Any cancer 
left in the treated zone only is termed “residual disease”. 
Radiographic suspicion of ablation failure is imaging sus-
pect for tumor presence within the treated zone. The pan-
elists unanimously agreed that multiparametric (mp) MRI 
is a suitable imaging tool for monitoring this, followed 
by 20 % for CEUS and 16 % for PET. Targeting failure 
occurs when the ablative energy is not correctly applied 
to the tumor spatially and for selection failure, FT was 
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Table 1  Definitions and consensus statements
Definition Consensus statement regarding definition
General definitions
Focal therapy (FT) An anatomy-based (zonal) treatment strategy (e.g. targeting a quadrant, a lobe or  
both lobes sub-totally)
Targeted FT A lesion-based focal treatment strategy targeting the identified tumors plus a safety margin
The aim of (targeted) FT for PCa Eradication of all significant cancer(s)
Subtotal ablation Any ablation where less than the whole gland is treated
Extended-hemiablation An ablation where one lobe is completely treated plus a margin of the other lobe  
regardless of shape
Index lesion The single dominant lesion in terms of grade and size where grade is more important. There can be 
only 1 index lesion. The term index lesion itself may be of limited use in the context of FT. It is 
more important to have an overview of all significant lesions that warrant treatment rather than a 
single defined index lesion
Salvage FT Salvage FT refers to the situation where FT is applied to the prostate after whole-gland  
therapy, or in the same region of the prostate as previous FT. The prostate gland has to be in 
place
Success and failure in focal therapy
Ablation failure Ablation failure is a failure of the technique to destroy the tissue in the treated zone, evidenced 
by tumor found within the treated zone. Ablation failure is just one of the causes that can lead 
to failure of FT as a whole. Other types of failure include targeting failure and selection failure. 
Must be confirmed by targeted biopsy
Radiographic suspicion of ablation failure A suspicion on imaging of tumor presence within the treated zone. mpMRI a suitable imaging 
modality to determine ablation failure
Residual disease Cancer remaining in the target zone after FT
Selection failure FT was inappropriately indicated, evidenced by short-term post-treatment identification of meta-
static or locally advanced disease. There is no agreement on whether significant PCa in short-
term biopsies taken inside or outside the treatment zone and the need for whole-gland treatment 
during follow-up constitute selection failure
Biochemical progression after targeted FT PSA is the best marker to monitor the disease after targeted FT. However, there is currently no data 
on how to use PSA, i.e. there is no data to support any of the definitions for biochemical recur-
rence in the context of (targeted) FT
Pathological progression An increase in Gleason score or tumor volume evidenced by a larger number of positive biopsies 
or larger per-core tumor involvement
Baseline and outcome functional measures
Functional success of FT The maintenance of voiding pattern, erectile function and quality of life assessed after 12 months
Erectile function A qualitative definition of impotency exists: the persistent inability to attain and maintain an erec-
tion sufficient for satisfactory sexual performance. For reporting research the panel recommends 
defining significant erectile dysfunction using the IIEF-5 score <21, determined at 1 year
Sexually active Patient-reported regular sexual activity
Urinary incontinence The need to use pads or patient-reported leakage. More comprehensive data could be gathered by 
requesting patients to complete a micturition diary including the parameters: number of pads, 
leakage and urge
Significant deterioration of urinary function An increase in IPSS >5 points
Quality of life A quality-of-life questionnaire should be administered and both the UCLA-EPIC and the EORTC-
QLQ-c-30 tools can be used although neither one is validated for the specific context of focal 
therapy
Bowel toxicity/GI side effects The occurrence of: a change in stool frequency, fistula formation, soiling and/or blood in the stool 
after FT should constitute bowel toxicity/GI side effects. There is no consensus on whether 
mucus in the stool should also be included. The use of one of the existing grading systems for 
bowel toxicity is recommended
Intraoperative complications Complications that cause damage to the patients’ health or require intervention to prevent damage
Short-term side effects Side effects within 90 days of the procedure
Serious side effects Clavien–Dindo-scale with 3 or greater as “serious” side effects
Procedural outcomes
Procedure time From the completion of anesthetic induction until the treating physician is finished
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inappropriately indicated to the patient. The panel agreed 
that selection failure was definitely evidenced by short-
term post-treatment identification of metastatic or locally 
advanced disease. However, during the meeting there was 
no agreement on how selection failure could be inferred 
from post-treatment biopsy results. There was agreement 
that PSA is the best marker to monitor disease activity after 
(targeted) FT, even though there is currently no data on 
how to use PSA after focal treatments where (malignant) 
prostate tissue is left in place. Therefore, there is no data 
to support any of the definitions for biochemical recurrence 
commonly used after whole-gland treatment in the con-
text of (targeted) FT. In defining pathological progression 
the panel agrees that both an increase in Gleason score and 
tumor volume evidenced by a growing number of positive 
biopsies or larger per-core tumor involvement should be 
taken into consideration.
Baseline and outcome functional measures
The panel recommended defining functional success of 
focal therapy as the maintenance of voiding pattern, erec-
tile function and QoL assessed after 12 months. In defining 
potency, most of the online panel agreed a minimum IIEF 
score should be used. During the face-to-face meeting, it 
was stressed that a widely endorsed qualitative definition of 
impotency already exists: “the persistent inability to attain 
and maintain an erection sufficient for satisfactory sexual 
performance”. However, a quantitative definition is useful 
in reporting and this quantitative definition should be based 
on the IIEF-5. The panel recommended defining significant 
erectile function following FT using the IIEF-5 score with 
a cut-off value of 21, determined at 1 year. The definition 
of sexually active should be based on patient-reported sex-
ual activity.
Urinary incontinence is defined as the need to use pads 
or patient-reported leakage. During the face-to-face meet-
ing, it was suggested that more comprehensive data should 
be gathered by requesting patients to fill in a voiding diary 
including: number of pads, leakage and urgency. The rec-
ommended definition of significant deterioration of urinary 
function is an IPSS increase >5 points.
In defining the QoL status of patients before and after 
FT different tools can be used. None of the tools were sup-
ported by more than 80 % of the panelists. The EORTC-
QLQ-C-30 was supported by 75 % of the panel and the 
UCLA-EPIC by 70 %. During the face-to-face meeting, 
there was agreement that a QoL questionnaire should be 
although neither one is validated in the specific context of 
FT.
In defining “bowel toxicity” following FT, the panel 
agreed that a change in stool frequency, fistula formation, 
or the occurrence or increase of soiling and blood in the 
stool after FT constitutes bowel toxicity. There is no con-
sensus on whether the occurrence or increased produc-
tion of mucus in the stool should be included. During the 
face-to-face meeting, a recommendation was formulated to 
use either one (CTCEA or RTOG/EORTC) of the existing 
grading systems for bowel toxicity. There was agreement 
that it may not be necessary to present a full questionnaire 
to all patients but only to those who have indicated that 
they have gastro-intestinal side effects.
The recommended definition of short-term side effects 
is: side effects that become apparent within 90 days after 
the procedure. The panel recommended including only 
complications to the definition of intraoperative complica-
tions that cause damage to the patients’ health or require 
a subsequent intervention. Therefore, technical difficul-
ties with the equipment and targeting difficulties due to 
anatomy are not necessarily intraoperative complications. 
The panel agreed to grade side effects using the Clavien–
Dindo-scale regarding a grade 3 and higher as “serious side 
effects”.
Procedural outcomes
The panel recommended defining procedural time as the 
time period starting after the anesthetic induction is com-
pleted and the treating physician can start until the treating 
physician has finished the treatment. Hospital stay should 
be defined as the time from admission until discharge. 
The definition of FT in day-care should be: admittance, 
treatment and discharge on the same calendar day. The 
definition of catheterization time should be the time from 
Table 1  continued
Definition Consensus statement regarding definition
Hospital stay The time from admittance until discharge
FT in day-care Admittance, treatment and discharge on the same day
Catheterization time The time from inserting the catheter until its removal, including time spent on the OR and the 
recovery-unit
All statements were accepted with >80 % consensus unless stated other otherwise
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inserting the catheter until its removal, including time spent 
on the OR and the recovery-unit.
Discussion
The results of this Delphi consensus project will aid 
researchers in reporting FT outcomes in a standardized 
fashion, thereby allowing comparison and also facilitat-
ing clear communication among patients, clinicians and 
researchers. As standardized definitions can only succeed 
if they are widely endorsed by the experts in the field, a 
large-group consensus project is the ideal way to achieve 
this. Consensus projects can be a valuable tool, especially 
in fields such as FT where the clinical evidence is still 
building. It is therefore not surprising that several consen-
sus projects on various aspects of FT have been undertaken 
in the past years. The topics handled in our consensus pro-
ject partly overlap with the topics of other consensus meet-
ings. There appears to have been a shift in the perceived 
aim of FT. The 2009 consensus project described by De la 
Rosette et al. [38] stipulated that the aim of FT is to eradi-
cate all known prostate cancer while preserving uninvolved 
tissue, sparing genitourinary function. The 2010 consensus 
project described by Ahmed et al. [39] stated the aim of FT 
is to treat cancer and leave benign prostate and surrounding 
normal structures. They do not note the possibility to also 
leave insignificant disease untreated. Five years later, we 
formulated the aim of FT to be the eradication of all identi-
fiable significant tumor(s). The consensus project described 
by Donaldson et al. [40] stated that FT should be the treat-
ment of the dominant lesion or index lesion. They add that 
quadrant ablation could be a FT strategy but with lower 
level of consensus than lesion ablation only. This may 
imply their panel considered FT as a lesion-based tech-
nique, similar to our definition of targeted FT. Consistent 
with the concerns regarding secondary (non-index) lesions 
harboring clinically significant disease with metastatic 
potential formulated by Reis et al. [41], the participants of 
our consensus project underlined the necessity to find and 
treat all clinically significant cancer foci, regardless of the 
precise definition of the index lesion.
The consensus projects described by Muller et al. [42] 
and De la Rosette et al. [38] provided definitions for onco-
logic success and oncologic efficacy, respectively, that are 
similar to our definition of ablation success: negative biop-
sies in the treated area. The definitions around the concepts 
of success and failure provided by the consensus project 
described by Van den Bos et al. [43] differed slightly from 
ours; they recommended defining in-field failure as: (1) 
higher Gleason grade disease in the treated zone, (2) persis-
tent cancer of similar or lower grade after repeat FT of the 
same area and (3) the need for additional treatment besides 
FT because of objective findings elsewhere in the gland. 
While the first two conditions are concordant with our defi-
nition of ablation failure, the latter does not. Finding tumor 
for which FT is not suitable during short-term follow-up 
elsewhere in the gland would constitute selection failure by 
our definition. Their definition of selection failure appears 
not to be related to adequate patient selection for FT but to 
the selection of tumor foci for treatment.
The project described by Muller et al. [42] described 
a definition of functional success comparable to ours: the 
absence of functional change in erectile function and ejacu-
latory function at 24 months, QoL at 24 months and urinary 
function at 12 months. The main difference is that present 
consensus does not include ejaculatory function and only 
uses the 12-month time point for all three domains of func-
tional outcomes.
The consensus projects by Muller et al. [42] and Van den 
Bos et al. [43] provided recommendations for follow-up 
after FT. Similar to our results, they recommended to moni-
tor PSA, although they also found no standardized defini-
tion of biochemical recurrence could be recommended. 
Other follow-up parameters include urinary function, sex-
ual function and quality of life using standardized tools, 
including IPSS and IIEF questionnaires. In the reviewed 
literature, FACIT (FACT-P) and (FACT-G) and UCLA-
EPIC questionnaires were the most prevalent tools for the 
assessment of QoL following FT. Muller et al. [42] could 
not achieve consensus on which QoL tool to be used, but 
the FACT-P was widely supported. In the project described 
by Van den Bos et al. [43], the UCLA-EPIC was recom-
mended, a least for pre-treatment assessment of QoL. De 
la Rosette et al. [38] also recommended to use the FACT-
P and EORTC questionnaire among several other options. 
In our project the EORTC-QLQ-c30 was widely endorsed 
besides the UCLA-EPIC, while the FACIT questionnaire 
was considered useful by only 50 % of our online panel. 
MpMRI is universally recommended as a tool for follow-
up after FT, which is consistent with our panel agreeing 
unanimously that mpMRI is a suitable tool to define radio-
graphic suspicion of ablation failure.
Several considerations regarding our consensus project 
are: as the results are based on expert opinion they amount 
to an Oxford Centre of Evidenced Based Medicine level 
5 of evidence [44]. The group of experts we invited may 
not be representative of the larger medical community 
as their involvement in FT makes them more likely to be 
enthusiasts. Furthermore, the response rates to our online 
questionnaires were between 59 and 65 %, although this 
is likely caused by our attempt to invite a large and broad 
group of experts, further bias in our results might be caused 
by “non-believers” not participating. Although a total of 38 
experts joined the face-to-face meeting, which took place 
at a FT meeting, their opinions may be more prominently 
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represented in the final recommendations than the opinions 
of the participants of the online rounds only. The repeti-
tive formulation and reformulation of questions and answer 
possibilities by the project leaders may also be a source of 
bias and can be seen as an inevitable limitation of the Del-
phi method.
Several important topics remain undefined because of 
consensus: (1) there was insufficient data (2) unresolved 
diverging opinions within the panel or (3) the topics were 
un-addressed by the current project. Examples of impor-
tant unresolved matters are: “What constitutes a clinically 
significant tumor focus?”, “How should PSA dynamics 
be interpreted after FT?”, “How can QoL best be assessed 
after FT” and “What are adequate safety margins to be 
observed for the different treatment modalities?”. These 
topics can be addressed in future consensus projects. As 
the data on FT accumulates, it should become possible 
to formulate stronger recommendations and data-based 
guidelines on how best to research, apply and report focal 
treatments.
Conclusion
Focal therapy is a rapidly evolving field of prostate can-
cer treatments that intends to prevent or delay whole-
gland treatment associated morbidity without compromis-
ing oncologic safety for a large group of patients. For the 
development and implementation of these treatments, it 
is important to have standardized reporting criteria. The 
current consensus project provides recommendations 
for standardized definitions endorsed by a wide group of 
experts in the field.
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